share_log

UBS Maintains Neutral on Teva Pharmaceutical Indus, Raises Price Target to $11

Benzinga ·  Sep 20, 2023 09:08

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Neutral and raises the price target from $8 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment